$1.15-0.00 (-0.43%)
Biote Corp. (BTMD) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for BTMD, including 1 earnings update. The most recent was published Oct 21, 2026.
Price$1.15-0.00 (-0.43%)
03:15 PM06:30 PM
News · 26 weeks26+100%
2026-05-032026-10-25
Mix590d
- Earnings2(40%)
- SEC Filings2(40%)
- Insider1(20%)
Latest news
25 items- PRBiote Schedules Third Quarter 2026 Financial Results Release and Conference Callbiote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide third quarter financial results on Wednesday, November 4, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will be
- INSIDERExecutive Chairman Beer Marc D bought $202,204 worth of shares (131,950 units at $1.53), increasing direct ownership by 122% to 239,744 units (SEC Form 4)4 - biote Corp. (0001819253) (Issuer)
- SECSEC Form 10-Q filed by Biote Corp.10-Q - biote Corp. (0001819253) (Filer)
- SECBiote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - biote Corp. (0001819253) (Filer)
- PRBiote Reports Second Quarter 2026 Financial ResultsContinued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights Revenue of $44.2 million Gross profit margin of 65.4% Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025 Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial
- PRBiote Schedules Second Quarter 2026 Financial Results Release and Conference Callbiote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day. Conference Call Details The conference call may be accessed by dialing (646) 307-1963 (U.S. toll-free) or (800) 715-9871 (International) and referencing conference ID: 1792102. The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings
- SECAmendment: SEC Form 8-K/A filed by Biote Corp.8-K/A - biote Corp. (0001819253) (Filer)
- INSIDERSEC Form 4 filed by Interim CEO Peterson Robert Charles4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Director Christensen Bret4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Executive Chairman Beer Marc D4 - biote Corp. (0001819253) (Issuer)
- SECBiote Corp. filed SEC Form 8-K: Leadership Update8-K - biote Corp. (0001819253) (Filer)
- PRBiote Appoints Komal Bajaj, MD, MS as Chief Medical OfficerBiote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro
- PRBiote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEOBret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting
- SECSEC Form 8-K filed by Biote Corp.8-K - biote Corp. (0001819253) (Filer)
- INSIDERSEC Form 4 filed by Director Heyer Andrew R4 - biote Corp. (0001819253) (Issuer)
- INSIDERDirector Morris Debra L converted options into 21,407 shares, increasing direct ownership by 43% to 71,562 units (SEC Form 4)4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Director Cone Stephen Mark4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Director Jacoby Dana Lynn4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Director Beer Marc D4 - biote Corp. (0001819253) (Issuer)
- INSIDERSEC Form 4 filed by Director Barrera Richard R4 - biote Corp. (0001819253) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biote Corp.SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)
- SECSEC Form 10-Q filed by Biote Corp.10-Q - biote Corp. (0001819253) (Filer)
- SECBiote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - biote Corp. (0001819253) (Filer)
- PRBiote Reports First Quarter 2026 Financial ResultsSales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners
- INSIDERSEC Form 4 filed by General Counsel Monico Daniel Michael4 - biote Corp. (0001819253) (Issuer)
BTMD FAQ
6 questionsWhat is the latest news on BTMD?
In the last 30 days Quantisnow tracked 1 wire item for BTMD: 1 earnings update. The most recent was published on October 21, 2026.Where does BTMD stock trade?
Biote Corp. (BTMD) is listed on NASDAQ.What sector and industry is BTMD in?
Biote Corp. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about BTMD?
Biote Corp. has had 4 recent analyst actions on file. The most recent action was from B. Riley Securities: Neutral with a $400.00 price target on 2025-08-07. Recent price targets range from $400.00 to $900.00.What companies are similar to BTMD?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), DFTX (Definium Therapeutics Inc.), RGC (Regencell Bioscience Holdings Limited). Compare BTMD side-by-side with any of them on Quantisnow.How can I track BTMD on Quantisnow?
Quantisnow aggregates Biote Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BTMD to receive live email and push alerts on every new disclosure.